Aclaris Therapeutics (ACRS) News Today $1.62 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.04 (-2.41%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Cantor Fitzgerald Issues Negative Forecast for ACRS EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Aclaris Therapeutics in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnMarch 21, 2025 | marketbeat.comCantor Fitzgerald Has Weak Forecast for ACRS FY2025 EarningsMarch 21, 2025 | americanbankingnews.comCantor Fitzgerald Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS)March 20, 2025 | americanbankingnews.comAclaris Therapeutics assumed with an Overweight at Cantor FitzgeraldMarch 19, 2025 | markets.businessinsider.comAclaris Therapeutics (NASDAQ:ACRS) Now Covered by Cantor FitzgeraldCantor Fitzgerald began coverage on shares of Aclaris Therapeutics in a research note on Tuesday. They set an "overweight" rating on the stock.March 19, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Connor Clark & Lunn Investment Management Ltd. lifted its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 173.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 908,819 shares of the biotechnology company's stock afterMarch 19, 2025 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Stock Crosses Below 50-Day Moving Average - Should You Sell?Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Crosses Below 50 Day Moving Average - Here's WhyMarch 18, 2025 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at ScotiabankScotiabank assumed coverage on shares of Aclaris Therapeutics in a report on Friday. They issued a "sector outperform" rating and a $15.00 price target on the stock.March 8, 2025 | marketbeat.comScotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform RecommendationMarch 8, 2025 | msn.comAclaris Therapeutics initiated with an Outperform at ScotiabankMarch 8, 2025 | markets.businessinsider.comResearch Analysts Set Expectations for ACRS FY2025 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal expectsMarch 7, 2025 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Strong-Buy at Cantor FitzgeraldCantor Fitzgerald raised shares of Aclaris Therapeutics to a "strong-buy" rating in a report on Tuesday.March 6, 2025 | marketbeat.comThis Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last YearMarch 5, 2025 | uk.finance.yahoo.comAclaris Therapeutics to Participate in Two March Healthcare ConferencesMarch 4, 2025 | globenewswire.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Buy" from AnalystsShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have given a strong buyMarch 4, 2025 | marketbeat.comQ1 Earnings Forecast for ACRS Issued By Leerink PartnrsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that theMarch 3, 2025 | marketbeat.comAclaris Therapeutics files $300M mixed securities shelfFebruary 28, 2025 | markets.businessinsider.comAclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings ResultsAclaris Therapeutics (NASDAQ:ACRS - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.February 28, 2025 | marketbeat.comAclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c)February 27, 2025 | markets.businessinsider.comAclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate UpdateFebruary 27, 2025 | finance.yahoo.comAclaris Therapeutics (NASDAQ:ACRS) Share Price Passes Below Fifty Day Moving Average - Here's WhyAclaris Therapeutics (NASDAQ:ACRS) Share Price Passes Below 50-Day Moving Average - Should You Sell?February 26, 2025 | marketbeat.comPiper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)February 18, 2025 | markets.businessinsider.comAclaris Therapeutics (ACRS) Projected to Post Earnings on TuesdayAclaris Therapeutics (NASDAQ:ACRS) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in JanuaryAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,920,000 shares, an increase of 15.6% from the January 15th total of 3,390,000 shares. Based on an average trading volume of 2,400,000 shares, the short-interest ratio is presently 1.6 days.February 15, 2025 | marketbeat.comPeapod Lane Capital LLC Invests $1 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Peapod Lane Capital LLC bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 404,452 shares of the biotechnology company's stock, valued at approxiFebruary 13, 2025 | marketbeat.comAclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 InhibitorFebruary 12, 2025 | msn.comAclaris Therapeutics announces publication describing properties of ATI-2138February 12, 2025 | markets.businessinsider.comNew Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3February 12, 2025 | globenewswire.comAclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' MoleculeFebruary 11, 2025 | seekingalpha.comStockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to SellStockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday.February 8, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for ACRS FY2025 Earnings?Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 EPS estimates for Aclaris Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biotechnology compaFebruary 7, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by AnalystsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recoFebruary 7, 2025 | marketbeat.comFY2029 Earnings Estimate for ACRS Issued By Leerink PartnrsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expFebruary 6, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in JanuaryAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,560,000 shares, a growth of 12.7% from the December 31st total of 3,160,000 shares. Based on an average trading volume of 2,410,000 shares, the short-interest ratio is presently 1.5 days.February 1, 2025 | marketbeat.comAclaris Therapeutics forms new Scientific Advisory BoardJanuary 30, 2025 | msn.comAclaris Therapeutics Announces Formation of New Scientific Advisory BoardJanuary 30, 2025 | globenewswire.comAssenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Assenagon Asset Management S.A. increased its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 113.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 397,362 sharJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Weighs in on ACRS FY2025 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology coJanuary 22, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest UpdateAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,560,000 shares, a growth of 12.7% from the December 15th total of 3,160,000 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 1.5 days.January 18, 2025 | marketbeat.comJane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Jane Street Group LLC reduced its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 75.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,727 shares of the biotechnology company's stock after selling 252,282 sJanuary 15, 2025 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommeJanuary 13, 2025 | marketbeat.comAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 6, 2025 | globenewswire.comShort Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 27.4%Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 3,160,000 shares, an increase of 27.4% from the November 30th total of 2,480,000 shares. Based on an average trading volume of 2,330,000 shares, the short-interest ratio is currently 1.4 days.December 29, 2024 | marketbeat.comHC Wainwright Has Strong Forecast for ACRS FY2024 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Investment analysts at HC Wainwright increased their FY2024 earnings estimates for shares of Aclaris Therapeutics in a note issued to investors on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now expects that the biotechnologyDecember 25, 2024 | marketbeat.comAclaris Therapeutics’ Strategic Licensing and Promising Pipeline Drive Buy RecommendationDecember 23, 2024 | markets.businessinsider.comAclaris Therapeutics upgraded to Buy from Neutral at H.C. WainwrightDecember 23, 2024 | markets.businessinsider.comHC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS)December 23, 2024 | msn.comAclaris Therapeutics (NASDAQ:ACRS) Upgraded at HC WainwrightHC Wainwright upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price objective for the company in a report on Monday.December 23, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Buy" by BrokeragesAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issueDecember 19, 2024 | marketbeat.comAclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy RatingDecember 18, 2024 | markets.businessinsider.com Remove Ads Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Media Mentions By Week ACRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼-0.330.78▲Average Medical News Sentiment ACRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼63▲ACRS Articles Average Week Remove Ads Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LENZ Therapeutics News Today Cronos Group News Today Prothena News Today ArriVent BioPharma News Today Organogenesis News Today CureVac News Today GH Research News Today Nuvation Bio News Today CorMedix News Today Immunome News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRS Stock Free ACRS Stock Alerts